The drugs have been named "CombiMab-1" and "CombiMab-2". Specialists from the Federal Biomedical Agency (FMBA) are working on them. The first vaccine has already undergone preclinical trials, while the trials for the second will be completed in the first quarter of 2026. The composition of the drugs includes a combination of three broadly neutralizing antibodies against HIV. HIV is the human immunodeficiency virus. Once it enters the body, it permanently resides in the cells and begins to destroy the body's defense functions (immunity). The final stage of HIV, when a person becomes completely defenseless against any infections and internal organs are affected, is called acquired immunodeficiency syndrome (AIDS). The "CombiMab-1" vaccine has passed the main stages of preclinical trials and its safety has been proven. Preparations for clinical trials are underway. The drug is capable of providing protection against a wide range of HIV variants for a period of at least one and a half years. The vaccine will increase the effectiveness of HIV infection therapy, avoid side effects, simplify the treatment regimen, and eliminate the need for daily intake due to its long-acting period. "The drug will be able to be used not only for treatment but also for the prevention of HIV infection, particularly in high-risk groups," the FMBA press service reported. According to last year's data, 921 thousand people are infected with HIV in Russia. Almost 97% of patients are officially registered. In 2023, the number of new infections decreased and was less than 55 thousand per year. At the same time, the level of population coverage with HIV testing is constantly growing and significantly exceeds the indicator in the European Union. The Ministry of Health has developed a special internet portal "About AIDS"